Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11753669 | 0.74 | CREBBP (0.40) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL9718691 | 0.69 | CREBBP (0.39) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL28448324 | 0.68 | CREBBP (0.53) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL17376745 | 0.67 | CREBBP (0.42) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL11750901 | 0.67 | GAA (0.38) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL30681543 | 0.64 | PNMT (0.56) | CREBBPGAAMAPTPNMTBRD4 | |
| SCHEMBL11748558 | 0.64 | MEN1 (0.36) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL24289281 | 0.63 | MEN1 (0.39) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL3319641 | 0.63 | CREBBP (0.39) | CREBBPBRPF1MEN1KMT2AGAA | |
| SCHEMBL8279432 | 0.63 | CREBBP (0.50) | CREBBPBRPF1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9003049-A | — | — | None | — | — | JP | disclosed |
| CN-106573896-B | Fluoroalkylating agents | KUMIAI CHEMICAL INDUSTRY CO.,LTD. (JP) | 2019-11-01 | — | — | CN | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-106573896-A | Fluoroalkylating agents | 庵原化学工业株式会社 | 2017-04-19 | — | — | CN | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| JP-H093049-A | SUBSTITUTED 2-TRIFLUOROMETHYL-2,3-DIHYDROBENZIMIDAZOLE ITS PRODUCTION AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | AGENCY OF IND SCIENCE & TECHNOL | 1997-01-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | CREBBP 114/4885BRPF1 2392/4885MEN1 1785/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CREBBP 2517/4885BRPF1 3464/4885MEN1 1618/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | CREBBP 936/4885BRPF1 4578/4885MEN1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.